



# Reimagine Employee Health with Cutting-edge Genetic Insights

Offer employees access to precision whole-genome risk assessments—empowering them to take control of their health while you reduce costs and maximize the impact of your benefits program.



## Enable Early Detection

Comprehensive, whole-genome-based risk screening uncovers hidden health risks early—enabling faster care to slow or prevent disease progression.

Genetic screening can **reduce** cancer treatment costs by up to

**~70%**

by enabling earlier detection<sup>1</sup>

## Personalize Preventative Interventions

Genetic results guide proactive care for conditions like coronary artery disease (CAD), enabling physicians to prescribe preventive medications, recommend lifestyle changes, and tailor screening plans.

Proactively treating genetically high-risk individuals can prevent CAD and **save** up to

**~\$40K**

per patient<sup>2</sup>

## Optimize Medication Selection

Personalized genetic insights can predict how an individual will respond to medication, which helps healthcare providers optimize medication selection and dosage to offset rising pharmacy costs and reduce treatment failure.

Genetics-informed medication plans can **lower** ER visits and in-patient stays by up to

**39%**

in high-risk populations<sup>3</sup>

# MyOme testing offers benefits to both employees and employers

## Enhanced Team Vitality



Improved employee health cuts absenteeism and boosts performance

## Reduced Healthcare Spend



Genetic health insights drive healthcare savings

## Strengthened Recruiting & Employee Retention



Standout benefits attract talent and increase appeal

## We're proud to be a partner you can trust

- › Our genetic testing is conducted in certified, clinical-grade laboratories. Results are shared securely through our HIPAA-compliant portal using enterprise-scale data encryption.
- › We provide comprehensive post-test support, including access to genetic counselors, to ensure employees understand their results and get their questions answered.
- › With MyOme, your employees own their data. We never sell or share data without their permission.



## Invest in the future of employee health with MyOme.

Contact us today to discover how our genetic solutions can improve health outcomes and reduce healthcare costs.

**1.** Reddy SR, Broder MS, Chang E, Paydar C, et al (2022). Cost of cancer management by stage at diagnosis among Medicare beneficiaries. *Current Medical Research and Opinion*, 38(8), 1285 – 1294. <https://doi.org/10.1080/03007995.2022.2047536>. **2.** Kazi D, Elkind M, Deutsch A, et al (2024). Forecasting the Economic Burden of CVD and Stroke in the US Through 2050. *Circulation*. 2024;150(4):e89–e101. doi:10.1161/CIR.0000000000001258. **3.** Fragala MS, Keogh M, Goldberg SE, et al (2024). Clinical and economic outcomes of a pharmacogenomics-enriched comprehensive medication management program in a self-insured employee population. *Pharmacogenomics J* 24, 30. <https://doi.org/10.1038/s41397-024-00350-1>.

This test was developed, and its performance characteristics were determined, by MyOme, Inc., a clinical laboratory certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and College of American Pathologist (CAP) accredited to perform high complexity clinical laboratory testing. This test has not been cleared or approved by the U.S. Food and Drug Administration (FDA). Test results should always be interpreted by a clinician in the context of clinical and familial data with the availability of genetic counseling when appropriate. MyOme is not responsible for the content or accuracy of third-party websites.